Profil
Dr. Kevin R.
McIntosh is Senior Research Director at Cognate BioServices, Inc.
Dr. McIntosh was previously employed as a Principal by Osiris Therapeutics, Inc.
He received his undergraduate degree from the University of Illinois, a graduate degree from the University of Illinois, and a doctorate degree from the University of Illinois.
Anciens postes connus de Kevin R. McIntosh
| Sociétés | Poste | Fin |
|---|---|---|
| OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Cognate BioServices, Inc.
 Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Directeur Technique/Scientifique/R&D | - |
Formation de Kevin R. McIntosh
| University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cognate BioServices, Inc.
Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |